ストックスクリーナーアプリを入手
64.63
2.36%
1.49
アフターアワーズ：
64.10
-0.53
-0.82%
前日終値:
$63.14
開ける：
$63.53
24時間の取引高:
8.44M
Relative Volume:
2.26
時価総額：
$7.20B
収益：
-
当期純損益:
$-96.75M
株価収益率:
-69.49
EPS:
-0.93
ネットキャッシュフロー:
$-71.95M
1週間 パフォーマンス:
-11.89%
1か月 パフォーマンス:
-0.51%
6か月 パフォーマンス:
-16.03%
1年 パフォーマンス:
+512.61%
1日の値動き範囲:
$62.50
$67.73
1週間の範囲:
$62.50
$79.10
52週間の値動き範囲:
$9.34
$99.41
Viking Therapeutics Inc Stock (VKTX) Company Profile
名前
Viking Therapeutics Inc
セクター
電話
858-704-4660
住所
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-05-31 | 再開されました | ROTH MKM | Buy |
| 2023-03-28 | 繰り返されました | Maxim Group | Buy |
| 2023-03-17 | 開始されました | Stifel | Buy |
| 2021-07-29 | 再開されました | BTIG Research | Buy |
| 2021-05-25 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 開始されました | BMO Capital Markets | Outperform |
| 2020-05-05 | 開始されました | Chardan Capital Markets | Buy |
| 2020-05-01 | 開始されました | BTIG Research | Buy |
| 2019-07-16 | 開始されました | Oppenheimer | Outperform |
| 2019-06-25 | 開始されました | Stifel | Buy |
| 2019-03-29 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 繰り返されました | Maxim Group | Buy |
| 2019-02-22 | 開始されました | SVB Leerink | Mkt Perform |
| 2018-12-12 | 開始されました | B. Riley FBR | Buy |
| 2018-11-19 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-09-18 | 繰り返されました | Maxim Group | Buy |
| 2018-09-18 | 繰り返されました | Raymond James | Outperform |
| 2018-07-20 | 開始されました | SunTrust | Buy |
| 2018-06-28 | 開始されました | Raymond James | Outperform |
| 2018-06-01 | 繰り返されました | Laidlaw | Buy |
| 2018-05-31 | 繰り返されました | Maxim Group | Buy |
| 2018-03-26 | 再開されました | H.C. Wainwright | Buy |
| 2017-11-28 | 繰り返されました | Maxim Group | Buy |
| 2017-11-21 | 開始されました | ROTH Capital | Buy |
すべてを表示
Viking Therapeutics Inc (VKTX) 最新ニュース
Viking Therapeutics Offers An Obesity Drug for Healthy Adults - Yahoo Finance UK
Viking stock fluctuates amid manufacturing concerns with obesity pill - Clinical Trials Arena
Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Sold by AlphaCentric Advisors LLC - MarketBeat
Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data - MSN
Viking Tops Novo As Obesity Pill Brawl Continues; But Shares Slash Massive Gains - MSN
Viking Therapeutics soars as early-stage oral obesity drug data exceeds expectations - MSN
Is Viking Therepautics a Buy Now? - Yahoo! Voices
Vanguard Group Inc's Strategic Acquisition in Viking Therapeutics - GuruFocus.com
Why Viking Therapeutics Stock Plummeted After Soaring Today - sharewise
Viking Therapeutics soars then drops on obesity data - CNBC
Viking's oral weight-loss drug seems impressive, but manufacturing questions linger - FirstWord Pharma
Health Care Down as GLP-1 Enthusiasm Wanes -- Health Care Roundup - Marketscreener.com
Viking Therapeutics' Hot Stock Slips After Latest Obesity Drug Trial Results - MSN
Obesity Pill Data Portend Competition, Hitting Drugmaker Shares - Bloomberg
Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat - Investor's Business Daily
Viking Therapeutics stock falling amid results for new GLP-1 pill - Yahoo Finance
Viking stock drops 13% after jumping 9% on obesity drug data (NASDAQ:VKTX) - Seeking Alpha
Viking Therapeutics (NASDAQ:VKTX) Stock Price Down 8.7%Time to Sell? - MarketBeat
Viking Therapeutics’ GLP-1 pill candidate shows promise in latest study - MM+M Online
Viking Therapeutics’ Early Clinical Data Continue to Build Case for Its Oral Obesity Drug - MedCity News
Viking Therapeutics’ weight-loss pill shows ‘great outcome’ in trial - MSN
Laidlaw maintains Buy on Viking Therapeutics, target at $110 - Investing.com
Stocks to Watch Monday: Trump Media, Viking Therapeutics, Nvidia, Intel - The Wall Street Journal
Viking Therapeutics Shines With Promising Results For New Obesity Drug - Finimize
Wall Street Lunch: Viking Therapeutics Thrives In Obesity Drug Saga (undefined:VKTX) - Seeking Alpha
Viking Therapeutics shares hold as Jefferies maintains Buy rating - Investing.com
Here's How I'm Trading Viking Therapeutics as the Stock Takes a Hit - TheStreet
What is Moving Viking Therapeutics Stock Today (VKTX)? - AskTraders
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations - Seeking Alpha
Viking Therapeutics stock jumps after ‘great’ trial of weight-loss drug - MSN
The Skinny on Viking Therapeutics Trial Results? Still a Little Thin - TheStreet
A new weight loss pill outperformed Novo Nordisk's version - Quartzy
Viking Therapeutics reports encouraging results from weightloss tablet - Proactive Investors UK
Viking Therapeutics, Roblox, Trump Media: 3 Stocks In Focus - Yahoo Finance
Viking Therapeutics (NASDAQ:VKTX) Shares Gap Up After Analyst Upgrade - MarketBeat
VKTX Stock: Viking Therapeutics Shares Surge 5% After Promising Results for Oral Obesity Drug - SpeaksLY
Viking Therapeutics Stock Soars, Picks Up Retail Buzz On ‘Promising’ Early Results For Obesity Pill - MSN
HC Wainwright Issues Positive Forecast for Viking Therapeutics (NASDAQ:VKTX) Stock Price - MarketBeat
H.C. Wainwright reiterated coverage on Viking Therapeutics with a new price target - Quantisnow
Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety - Benzinga
Viking Therapeutics stock jumps after weight-loss pill shows ‘great outcome’ in trial - MSN
Stock to Watch Monday: Trump Media, Viking Therapeutics, Nvidia, Intel - The Wall Street Journal
Viking's oral obesity med sails ahead, posting 6.8% weight loss for highest dose in phase 1 - Fierce Biotech
Viking Thera highlights obesity candidate VK2735 - The Pharma Letter
Trending tickers: Berkshire Hathaway, Ryanair, Viking Therapeutics, Burberry - Yahoo Finance UK
Novo Nordisk share price falls after Viking Therapeutics pill update - Marketscreener.com
Viking Therapeutics’ Promising Results for Obesity Treatment - TipRanks
Viking Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024 - Quantisnow
Viking Therapeutics Stock Soars on New Obesity Data. Why It Shows the Future of GLP-1 Drugs. - Barron's
Nvidia, Apple, Sherwin-Williams, DJT, Talen Energy, Viking Therapeutics, and More Movers - Barron's
Viking Therapeutics Inc (VKTX) 財務データ
収益
当期純利益
現金流量
EPS
Viking Therapeutics Inc (VKTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ZANTE GREG | Chief Financial Officer |
Oct 28 '24 |
Sale |
76.61 |
131,687 |
10,089,164 |
149,366 |
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):